What is NAD+?

A coenzyme, not a peptide, that every human cell makes and uses in redox reactions, including mitochondrial ATP (energy) production.

At a glance

What it is
A coenzyme, not a peptide, that every human cell makes and uses in redox reactions, including mitochondrial ATP (energy) production.
Also called
NAD · NAD+ · beta-nicotinamide adenine dinucleotide (beta-NAD) · nadide
US status
503A basis to verifyPharmacies compound it, but FDA has not confirmed the basis a 503A pharmacy relies on.
Evidence
C: Small or uncontrolled human dataFor injected or IV NAD+, 32 people in published studies, who were measured for blood levels and tolerability only; trials of oral precursors exist but test a different product, and we found no human trial of energy, cognition or "anti-aging" outcomes.
Safety signal
Known serious riskProduct quality (16 recalls, one Class I endotoxin lot with 3 ER visits)No data (unknown ≠ safe)Long-term repeated use, pregnancy, under-18s

Status checked Nov 16, 2026 · To verify

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Randomized controlled trials18Measured: blood NAD+, infusion time and tolerability in 18 people given NAD+ by IV (10 in one study, 8 in a second), in a small randomized pilot registered as NCT06382688; it is a preprint, not peer-reviewed, and has industry links, with NR supplied by W.R. Grace and ChromaDex (Hawkins 2024).14
Controlled studies11Measured: NAD+ and related molecules in blood plasma and urine during a 6-hour IV infusion in 11 men aged 30 to 55 (8 given NAD+, 3 controls), in a pilot whose authors include NAD+ Research Inc. and a wellness center (Grant 2019).1334
Observational studies14Measured: infusion time and symptoms during infusion in 6 people given NAD+ by IV on four days in a row and 8 given NR by IV at a commercial IV clinic, in a look back at their charts by authors employed by Restore Hyperwellness, with NR donated by Niagen Bioscience (Reyna 2026).1537
Registered trials53Registered trial NCT06382688, randomized, of IV NR vs IV NAD+ vs saline vs oral NR, with 53 enrolled; its status is unknown, last updated April 24, 2024, and its sponsor is the Nutraceuticals Research Institute.1735

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Registered trialsNot statedRegistered trial NCT06919328 of NAD+ given into muscle, under the skin and by IV push vs Niagen+, about 70 people, "enrolling", sponsored by the Nutraceuticals Research Institute.18
Registered trials26Registered trial NCT07475546 (AgelessRx, completed, 26 enrolled) of NAD+ nasal spray as one part of a combination with several other drugs, so it cannot isolate NAD+.35
Reviews489Reviewed: 10 randomized trials of oral NADH and NAD+ precursors, with 489 participants; this does not apply to injected or IV NAD+ (Gindri 2024 systematic review).16
ReviewsNot statedReviewed: studies from 2018 to 2026 of IV NAD+ and NAD+ precursors in wellness and translational medicine, in a narrative review (Alangari 2026).36

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
"Supercharge cellular energy and repair"NAD+ has a known role as a coenzyme, but we found no human outcome data for injected NAD+.15F
"DNA repair enhancement"NAD+ is a cofactor for DNA-repair enzymes, but we found no human outcome data.15F
"Cognitive function improvement"We found no human data for injected or IV NAD+; trials of oral NADH in Alzheimer's disease test a different product.16F
"Improve mitochondrial function"We found no human outcome data.15F

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
"Supports cognitive function and reduces brain fog"We found no human study of nasal NAD+.F
"rapid entry into the bloodstream and brain" (nasal)We found no study of this.F
"Enhances cellular repair and energy production"This rests on NAD+'s biology only.15F
"helps support cellular energy production"Accurate as a description of NAD+'s biology, but no study shows an outcome from taking it; small IV studies measured blood levels only.1315C
Implied relief of "slower recovery" / "reduced mental sharpness"We found no study.F
"mitochondrial energy production, DNA repair, cellular stress responses"An accurate description of NAD+'s biology, not a claim about outcomes; we found no outcome data.1530F
Raises blood NAD+Small pilot studies in people measured blood NAD+ during and after IV infusion.1314C
"Oral NAD+ ... not absorbed intact"Researchers state that NAD+ is not directly absorbed by the gut.1525C

Safety facts

Reports to the FDA

  • The FDA's adverse event database (FAERS, data to October 28, 2026) holds 48 reports with a drug named "NAD" or "NAD+", 29 marked serious, and 31 of them from 2025 or 2026; the top terms are fatigue (8), headache (6), nausea (6), anxiety (5), redness (5) and insomnia (5). Many of these reports also name vitamins and supplements and record no route, so oral products and injections cannot be told apart; the reports are not checked and do not show that NAD+ caused the event.38

What the FDA has said

  • The FDA has cited NAD+ products as unapproved new drugs, as misbranded for inadequate directions for use, as adulterated because of endotoxin, and as not eligible under 503B.89

In studies and reviews

  • A 2026 review lists nausea, cramping, flushing and chest discomfort as effects reported across studies, and says long-term safety data are lacking (Alangari 2026).36
  • Reactions during IV infusion were common in Hawkins 2024: most people given NAD+ by IV reported discomfort, including nausea, headache, diarrhea, chest tightness, lightheadedness, cramping and anxiety, which went away after the infusion ended. NAD+ infusions took about 3 hours on average, against about 2 hours for NR.14
  • In Reyna 2026, all 6 of 6 people given NAD+ by IV reported moderate to severe stomach cramping, nausea, vomiting, a faster heart rate and chest pressure during the infusion, which went away when it ended. NAD+ infusions averaged 97 minutes, against 37 for NR, and took longer because of the symptoms.1537
  • In Hawkins 2024, neutrophil and white blood cell counts were higher at 3 hours in the NAD+ IV group, which the authors said may reflect an inflammatory response.14

No data

  • We found no human safety data for pregnancy and breastfeeding, people under 18, people with cancer, or people with kidney, liver or heart disease. Pharmacy and program pages advise avoiding NAD+ in these groups.2527
  • We found no data on the long-term safety of repeated injections.

Product quality

  • The FDA documented an NAD+ lot with endotoxin of 3,360 EU/mL: three patients had low blood pressure, uncontrollable shaking and body aches and were sent to the emergency room. The lot, distributed nationwide, was recalled in a Class I recall.833
  • The FDA's warning letter to Thrive notes that Thrive recalled all repackaged sterile products it dispensed from January 2 to April 18, 2025, for lack of sterility assurance; FDA recall records list two of them as NAD+ 100 mg/mL pre-filled syringes. The NAD+ named in the letter was 50 mg/mL.933
  • FDA recall records list 16 recalls of NAD or NAD+ injections from 8 firms, started between 2017 and 2026: 1 Class I (GenoGenix, for endotoxin) and 15 Class II.33
  • By reason, the 16 NAD and NAD+ injection recalls were for lack of sterility assurance (11), failed potency or reconstitution time (2), high endotoxin (1), deviations in good manufacturing practice (CGMP) monitoring (1) and beyond-use date labeling (1).33
  • By the year they started, the NAD and NAD+ injection recalls number 1 in 2017, 1 in 2018, 1 in 2019, 2 in 2020, 5 in 2022, 1 in 2023, 4 in 2025 and 1 in 2026.33
  • The latest recall is Apothecary Pharma's NAD+ 200 mg/mL, started September 24, 2026 for lack of sterility assurance, and still ongoing.33

Compounded NAD+ is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Requires a prescription, after an evaluation by a prescriber (MD, DO, NP or PA) licensed in your stateLegal
  • Names the pharmacy that fills it and says whether it is a 503A pharmacy (for one patient's prescription) or a 503B facility; since the FDA has said NAD+ is not eligible under 503B, a 503B source should be questioned8LegalGood practice
  • Uses a pharmacy licensed in your state, with a license you can look upLegal
  • States plainly that compounded NAD+ is not FDA-approved and that no FDA-approved NAD+ drug exists29Good practice
  • Never sells "research use only" or "not for human use" NAD+Legal
  • Shows a certificate of analysis or third-party tests for sterility and endotoxin, and a beyond-use date833Good practice
  • Lists the common side effects of infusions and injections (nausea, cramping, chest tightness, flushing), and tells you to stop and seek care for a severe reactionGood practice
  • Has IV infusions given only by licensed clinicians in a licensed setting32Legal
  • States the amount, the route, how often, and how to store it, refrigeration includedGood practice
  • Makes no claim to treat a disease (addiction, Alzheimer's, Parkinson's) and no "anti-aging" guaranteeLegal
  • Shows the price, subscription, cancellation and refund terms before checkoutLegalGood practice
  • Tells athletes about the USADA and WADA limit on IV infusions (over 100 mL in 12 hours is prohibited)21Good practice
  • Uses only real testimonials, labeled as such, with no made-up "example experiences"Legal

  1. 1.
  2. 2.
  3. 3.
    FDA, "Bulk Drug Substances Used in Compounding Under Section 503B"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  4. 4.
  5. 5.
  6. 6.
    Federal Register, Apr 16, 2026, Doc. 2026-07361 (PCAC meeting notice)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
  7. 7.
    FDA, PCAC July 23–24, 2026 meeting pageTier 1: regulator or registerfda.govread Nov 16, 2026↩
  8. 8.
    FDA Warning Letter, GenoGenix LLC, 718739 (Jan 20, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  9. 9.
    FDA Warning Letter, Thrive Health and Wellness LLC, 714891 (Feb 9, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  10. 10.
  11. 11.
    Nutritional Outlook, "FDA responds to citizen petitions on NMN..." (Sep 30, 2025)Tier 3: reference, law firm or pressnutritionaloutlook.comread Nov 16, 2026↩
  12. 12.
    Venable LLP, "FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement" (Oct 2, 2025)Tier 3: reference, law firm or pressvenable.comread Nov 16, 2026↩
  13. 13.
  14. 14.
  15. 15.
    Reyna K. et al., retrospective tolerability pilot of IV NAD+ vs NR, Frontiers in Aging 2026;7:1652582Tier 2: peer-reviewed or trial registryfrontiersin.orgread Nov 16, 2026↩
  16. 16.
  17. 17.
    NCT06382688 (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026↩
  18. 18.
    NCT06919328 (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026↩
  19. 19.
  20. 20.
  21. 21.
    USADA, "IV Infusions: Explanatory Note" (modified Jul 14, 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
  22. 22.
  23. 23.
    DEA Diversion, Controlled Substances – Alphabetical Order (Nov 12, 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  24. 24.
    USP–NF, Dietary Supplement Monograph: Nicotinamide Riboside ChlorideTier 3: reference, law firm or pressdoi.usp.orgread Nov 16, 2026↩
  25. 25.
    Empower Pharmacy, NAD+ Injection (Aqueous)Tier 4: lead onlyempowerpharmacy.comread Nov 16, 2026↩
  26. 26.
    BetterMe Rx NAD+ advertorialTier 4: lead onlybettermerx.comread Nov 16, 2026
  27. 27.
    Superpower, NAD+ Injection product pageTier 4: lead onlyclinic.superpower.comread Nov 16, 2026↩
  28. 28.
  29. 29.
    Midi Health, NAD+ Nasal Spray product monographTier 4: lead onlyjoinmidi.comread Nov 16, 2026
  30. 30.
    Eden press release (via B2B Local)Tier 4: lead onlynews.b2blocal.comread Nov 16, 2026↩
  31. 31.
    Partnership for Safe Medicines statement (Jul 22, 2026)Tier 4: lead onlysafemedicines.orgread Nov 16, 2026
  32. 32.
    News12 Bronx, "Prosecutors: unauthorized NAD+ IV infusion led to woman's death" (Jul 21, 2026)Tier 3: reference, law firm or pressbronx.news12.comread Nov 16, 2026↩
  33. 33.
  34. 34.
    Grant R et al., Front Aging Neurosci 2019;11:257, full text PMC6751327 (Methods: participants)Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
  35. 35.
  36. 36.
  37. 37.
    Reyna K et al., Front Aging 2026;7:1652582, PubMed abstract PMID 41704678Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
  38. 38.
  39. 39.
  40. 40.
  41. 41.
    FDA Warning Letter, ProRx LLC, MARCS-CMS 723704 (Apr 7, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  42. 42.
  43. 43.
  44. 44.

We review programs, not the drugs they sell. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.